DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Neutral impactCorporate Action

Alembic Pharmaceuticals Limited — Change in Directors/KMP/SMP/Auditor/RTA

NSE 2 hrs ago·10 Aug 2026, 1:37 pm

Company NSE

Alembic Pharmaceuticals has informed stock exchanges about a change in its key management personnel and auditors. This corporate filing indicates a shift in the company's leadership structure, which is a routine administrative update.

For investors, such changes are generally neutral events unless accompanied by specific reasons. They do not inherently signal a change in the company's financial health or operational strategy. The focus should remain on the firm's core business performance and product pipeline.

Investors should watch for any official statements from the company regarding the rationale behind these changes. Monitoring the new leadership's strategy will be key to understanding if this move impacts the company's future direction.